The Lyme disease vaccine: conception, development, and implementation.
Thanassi W, Schoen R. The Lyme disease vaccine: conception, development, and implementation. Annals Of Internal Medicine 2000, 132: 661-8. PMID: 10766685, DOI: 10.7326/0003-4819-132-8-200004180-00009.Peer-Reviewed Original ResearchSafety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
Schoen R, Sikand V, Caldwell M, Van Hoecke C, Gillet M, Buscarino C, Parenti D. Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clinical Therapeutics 2000, 22: 315-325. PMID: 10963286, DOI: 10.1016/s0149-2918(00)80035-1.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineThird doseRecombinant outer surface protein A (OspA) vaccineOuter surface protein A (OspA) vaccineRecombinant outer surface proteinGeometric mean antibody titersVaccine 1 monthMost adverse eventsDoses of vaccineMean antibody titersLyme disease endemic areaEnzyme-linked immunosorbentDisease-endemic areasA vaccineAdverse eventsRandomized studyVaccination scheduleImmunogenicity profileSafety profileAntibody titersMonths 0Month 2Clinical trialsEfficacy trials